<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955654</url>
  </required_header>
  <id_info>
    <org_study_id>SMHC-OCD-002</org_study_id>
    <nct_id>NCT02955654</nct_id>
  </id_info>
  <brief_title>Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder</brief_title>
  <official_title>Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether acceptance and commitment therapy is
      effective in the treatment of SSRIs-resistant obsessive- compulsive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients who were SSRI-resistant will be randomized to ACT, aripiprazole, or SMT.
      Independent evaluators, blind to treatment,will evaluate patients during the study.The
      Yale-Brown Obsessive Compulsive Scale (YBOCS)will be used to measure OCD severity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>0,8week</time_frame>
    <description>Change from baseline Y-BOCS score at 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II</measure>
    <time_frame>0,8week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance and Action Questionnaire</measure>
    <time_frame>0,8week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Evaluation Inventory-Short Form</measure>
    <time_frame>0,8week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic life sign</measure>
    <time_frame>0,8week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>0,8week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Involuntary Movement Scale</measure>
    <time_frame>0,8week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Acceptance and commitment therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stress management training</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Acceptance and commitment therapy</intervention_name>
    <description>Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.</description>
    <arm_group_label>Acceptance and commitment therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress management training</intervention_name>
    <description>Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.</description>
    <arm_group_label>Stress management training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age between 18 and 65;

          2. no less than 9 years in education;

          3. a DSM-IV diagnosis of OCD

          4. moderately symptomatic (Yale-Brown Obsessive Compulsive Scale score≥16)

          5. received at least two kinds of SSRIs at optimal dose for more than 12 weeks An optimal
             dose is described as following: clomipramine hydrochloride, at least 225
             mg/d;fluoxetine, at least 60 mg/d; paroxetine hydrochloride, at least 60 mg/d;
             sertraline hydrochloride, at least 200 mg/d; fluvoxamine, at least 250 mg/d;
             citalopram hydrobromide,at least 60 mg/d; and escitalopram oxalate, at least 40
             mg/d.Patients who are unable to tolerate the supposed optimal doses were also eligible
             if at their maximally tolerated dose.

        Exclusion Criteria:

          1. with comorbid Axis I psychiatric disorders

          2. drug abuse in the last 3 months

          3. HAMD&gt;25

          4. too severe to receive ACT or evaluation

          5. at high risk of suicide

          6. pregnant or prepare for pregnancy

          7. with somatic disorder

          8. received aripiprazole(≥10mg for 8weeks) or ACT(8 times within 2 months) before

          9. treated with no more than one kind of SSRI before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Wang, Ph.D M.D</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen Wang, Ph.D M.D</last_name>
    <phone>862164387250</phone>
    <phone_ext>73516</phone_ext>
    <email>wangzhen@smhc.org.cn</email>
  </overall_contact>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

